Quick Answer
Sunshine Biopharma Inc. reported Research And Development Expense of $933.9 thousand for the year ending 2024.
- Sunshine Biopharma Inc. showed a decrease of -49.7% in Research And Development Expense from 2023 to 2024.
- This data is from Sunshine Biopharma Inc.'s annual report (Form 10-K), filed with the SEC on April 1, 2025.
- XBRL data for this metric is available from 2010 to 2024 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Historical annual values: Fiscal year 2024: $933.9 thousand | Fiscal year 2023: $1.86 million | Fiscal year 2022: $811.9 thousand | Fiscal year 2021: $672.2 thousand | Fiscal year 2020: $1.7 thousand | Fiscal year 2019: $15.2 thousand | Fiscal year 2018: $12.8 thousand | Fiscal year 2017: $0.00 | Fiscal year 2016: $32.8 thousand | Fiscal year 2015: $8.7 thousand | Fiscal year 2014: $327.0 thousand | Fiscal year 2013: $137.4 thousand | Fiscal year 2012: $1.8 thousand | Fiscal year 2011: $142.7 thousand | Fiscal year 2010: $0.00.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: